TG Therapeutics Mourns the Loss of Board Member, William J. Kennedy, PhD
June 29 2021 - 7:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced with great
sadness the passing of longtime Board Member, William J. Kennedy,
PhD.
“It is with deep sorrow we announce the passing of Bill, one of
the first Directors to join our board, and someone I personally
considered a good friend, advisor and mentor. Bill has been an
integral part of the TG team and helped shape and guide our
regulatory strategy. On behalf of our board and team, we extend our
deepest sympathies to Bill’s family and friends during this
difficult time. He will be sorely missed by all of us at TG,”
stated Michael S. Weiss, the Company's Chairman and Chief Executive
Officer.Bill Kennedy earned bachelor’s and master’s degrees each in
biology from Siena College Clark University and earned his PhD in
pharmacology from SUNY Buffalo. Throughout his career he worked for
several pharmaceutical companies eventually becoming the Executive
Vice President of Drug and Regulatory Affairs at Zeneca
Pharmaceuticals. His proudest professional accomplishment was his
assistance with the development and passage of the Food and Drug
Administration Modernization Act of 1997, Public Law 105-115, which
included the reauthorization of the crucial Prescription Drug User
Fee Act. After retirement his proudest personal accomplishment was
authoring three novels about a CIA operative spy, Jonathan West.
First Kill, Morally Grey and The Pentagon Years have received rave
reviews from readers.
ABOUT TG THERAPEUTICS, INC.TG
Therapeutics is a fully-integrated, commercial stage
biopharmaceutical company focused on the acquisition, development
and commercialization of novel treatments for B-cell malignancies
and autoimmune diseases. In addition to an active research pipeline
including five investigational medicines across these therapeutic
areas, TG has received accelerated approval from
the U.S. FDA for UKONIQ® (umbralisib), for the
treatment of adult patients with relapsed/refractory marginal zone
lymphoma who have received at least one prior anti-CD20-based
regimen and relapsed/refractory follicular lymphoma who have
received at least three prior lines of systemic therapies.
Currently, the Company has three programs in Phase 3 development
for the treatment of patients with relapsing forms of multiple
sclerosis (RMS) and patients with chronic lymphocytic leukemia
(CLL) and several investigational medicines in Phase 1 clinical
development. For more information,
visit www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and Linkedin.UKONIQ® is a
trademark of TG Therapeutics, Inc. is a trademark of TG
Therapeutics, Inc.
CONTACT: |
|
|
|
|
Investor
RelationsEmail: ir@tgtxinc.comTelephone: 1.877.575.TGTX
(8489), Option 4Media Relations:Email:
media@tgtxinc.comTelephone: 1.877.575.TGTX (8489), Option 6 |
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024